Strategic Endocrine Therapy and Targeted Radiotherapy for Prostate Cancer
This study is looking at how long men with high-risk prostate cancer need to receive hormone therapy (androgen deprivation therapy, or ADT) when combined with radiation therapy. Researchers want to see if giving ADT for 6 months works as well as giving it for the usual 18 months. They will also check the safety of these treatments. You may be able to join if you are a man aged 18 or older with prostate adenocarcinoma (a common type of prostate cancer) that is considered high-risk, based on your PSA level or Gleason score. The main goal is to see if patients who get the shorter ADT need other hormone therapy or develop castration resistance (when the cancer stops responding to hormone therapy) within 5 years at a higher rate.
- Study design
- This is an interventional study with a planned enrollment of 150 participants. The specific phase of the study is not provided.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for up to 5 years to see if the treatment was successful.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Strategic Endocrine Therapy and Targeted Radiotherapy for Prostate Cancer
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Tyler Seibert, MD, PhD · PRINCIPAL_INVESTIGATOR · University of California, San Diego
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Failure-free survivalWithin 5 years
To compare failure-free survival of radiotherapy plus short-term androgen deprivation therapy plus, if indicated, an androgen receptor pathway inhibitor to that of radiotherapy plus long-term androgen deprivation therapy. Participants will be considered to have failure-free survival if they do not experience any of the events in the 5 years after the end of radiation therapy: 1. Death from any cause. 2. Initiation of salvage hormone therapy as defined in the protocol. 3. Castration resistance per the Prostate Cancer Clinical Trials Working Group 3 definition. Castration resistance is defined as biochemical or clinical progression - as defined in the protocol - while serum testosterone is at castrate levels (\<50 ng/dL).